Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESOLVE
- Sponsors Gilead Sciences
- 18 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
- 23 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
- 22 Apr 2016 New trial record